No Data
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.
Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.
Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $75
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $67 to $75.
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (PRCT), Springworks Therapeutics (SWTX) and Omnicell (OMCL)